JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holycross, B. J.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holycross, B. J.
Right arrow Articles by Jackson, E. K.

Adenosine-angiotensin II interactions. Part II. The role of adenosine in regulating angiotensin II-induced changes in heart rate and aldosterone release

BJ Holycross, P Li and EK Jackson

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.

The purpose of the present study was to determine whether endogenous adenosine (ADO) participates in angiotensin II (AII)-induced decreases in heart rate (HR) and regulates AII-induced aldosterone (ALDO) release. To test these hypotheses we investigated: 1) the effects of ADO and AII on base-line HR and ALDO levels; 2) the effects of ADO on AII-induced bradycardia and AII-induced increases in ALDO levels; 3) the effects of ADO receptor antagonists [caffeine and/or 1,3-dipropyl-8- p-sulfophenylxanthine (DPSPX)] on AII-induced bradycardia and AII- induced increases in ALDO levels; and 4) the effects of ADO receptor hypersensitivity on AII-induced bradycardia. In the latter experiments, the animals were rendered hypersensitive to the bradycardic effects of ADO by administering caffeine for 1 week then abruptly withdrawing caffeine 18 hr before the experiment, i.e., caffeine withdrawal. Intravenous infusions of either ADO or AII decreased base-line HR and ADO reduced the bradycardic response to AII. Intravenous infusions of DPSPX attenuated and caffeine withdrawal potentiated AII-induced bradycardia without modifying AII-induced increases in arterial blood pressure. AII increased and ADO did not alter base-line plasma ALDO levels; however, ADO attenuated by 50% AII-induced increases in ALDO levels. Neither DPSPX nor caffeine altered the ability of AII to increase plasma ALDO levels. These results indicate that although ADO has the potential to modulate AII-induced increases in plasma ALDO concentrations, endogenous ADO does not regulate the effects of AII on plasma ALDO levels under the conditions of these studies. However, endogenous ADO, in some way, contributes substantially to AII-induced bradycardia.

Volume 250, Issue 2, pp. 442-453, 08/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics.